润达医疗 2021 年年度报告 公司代码：603108 公司简称：润达医疗 转债代码：113588 转债简称：润达转债 上海润达医疗科技股份有限公司 2021 年年度报告 1 / 314 润达医疗 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 亚太（集团）会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人赵伟东、主管会计工作负责人廖上林及会计机构负责人（会计主管人员）李娜声 明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 2022年4月25日，公司召开第四届董事会第二十一次会议，审议通过了《关于2021年度不进行 利润分配的议案》。同意公司2021年度不进行现金红利，不送红股，不以公积金转增股本。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，请投 ...

2021 年第三季度报告 单位：元 币种：人民币 证券代码：603108 证券简称：润达医疗 转债代码：113588 转债简称：润达转债 上海润达医疗科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |------------------------------------------------|------------------|-----------------------------------------|------------------| ...

2021 年第三季度报告 单位：元 币种：人民币 证券代码：603108 证券简称：润达医疗 转债代码：113588 转债简称：润达转债 上海润达医疗科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |------------------------------------------------|------------------|-----------------------------------------|------------------| ...

2021 年半年度报告 公司代码：603108 公司简称：润达医疗 转债代码：113588 转债简称：润达转债 上海润达医疗科技股份有限公司 2021 年半年度报告 1 / 257 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人赵伟东、主管会计工作负责人廖上林及会计机构负责人（会计主管人员）李娜声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，请投资者 注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内 ...

Financial Performance - The company's operating revenue for 2020 was approximately ¥7.07 billion, a slight increase of 0.24% compared to ¥7.05 billion in 2019[27]. - Net profit attributable to shareholders for 2020 was approximately ¥329.98 million, representing a growth of 6.61% from ¥309.51 million in 2019[27]. - The net cash flow from operating activities increased by 31.12% to approximately ¥323.44 million in 2020, compared to ¥246.68 million in 2019[27]. - Total assets as of the end of 2020 reached approximately ¥10.18 billion, a 12.66% increase from ¥9.03 billion at the end of 2019[27]. - The net assets attributable to shareholders increased by 16.13% to approximately ¥3.20 billion at the end of 2020, compared to ¥2.76 billion at the end of 2019[27]. - The company reported a net profit excluding non-recurring gains and losses of approximately ¥322.81 million in 2020, up 5.94% from ¥304.71 million in 2019[27]. - Basic earnings per share for 2020 increased by 8% to CNY 0.57 compared to CNY 0.53 in 2019[28]. - The net profit attributable to shareholders for Q4 2020 was CNY 94,189,788.06, with a total annual revenue of CNY 2,144,276,728.69 for the same quarter[30]. Dividend Policy - The company approved a cash dividend of 1.14 CNY per 10 shares, totaling 66,067,139.11 CNY, which accounts for 20.02% of the net profit attributable to shareholders in 2020[6]. - The company plans to distribute at least 20% of its distributable profits as cash dividends in the future, contingent on achieving positive net profits and having retained earnings[134]. - The company has committed to maintaining a cash dividend policy that prioritizes cash distributions while considering its growth potential[134]. Audit and Compliance - The company received a standard unqualified audit report from Asia-Pacific (Group) CPA[5]. - The board of directors and supervisory board members confirmed the accuracy and completeness of the annual report[3]. - There were no non-operating fund occupations by controlling shareholders or related parties[8]. - The company has not violated decision-making procedures for external guarantees[8]. - The company has not faced any issues with more than half of the directors being unable to guarantee the authenticity of the annual report[8]. - The company is committed to ensuring compliance with regulations and maintaining fair practices in related party transactions to protect shareholder interests[137]. Market and Growth Strategy - The company is focused on expanding its market presence and enhancing its product offerings through new technology development[19]. - Runda Medical aims to leverage its existing partnerships to drive innovation and improve service delivery in the healthcare sector[19]. - The company plans to explore potential mergers and acquisitions to accelerate growth and market expansion[19]. - The company aims to deepen its focus on in vitro diagnostic services and expand its national service platform over the next 3-5 years[128]. - The company plans to enhance its self-owned brand product system and accelerate market expansion to capture a larger market share[128]. - The company intends to improve service depth and breadth by leveraging information technology tools and exploring new growth points[130]. Research and Development - The company invested over 87 million yuan in R&D, marking a year-on-year increase of 46.48%[77]. - The company’s R&D efforts focus on in vitro diagnostic products and medical information systems, enhancing its service capabilities[37]. - The company has a strong IT team of over 200 personnel focused on developing information systems for the IVD field, enhancing management efficiency and service quality[69]. - The company has successfully launched its self-developed HbA1c analyzer and related reagents, capturing a significant market share in the domestic market[71]. - The company has developed 37 reagent registration certificates for its chemiluminescence detection system, with over 30 projects currently under research[71]. Risk Management - The company detailed various risks faced in production and operations, along with corresponding countermeasures[8]. - The report includes a forward-looking statement risk declaration, emphasizing that future plans do not constitute a commitment to investors[7]. - The company faces risks from intensified market competition and potential increases in accounts receivable due to longer collection cycles[131]. - The company will optimize its financing structure and enhance capital strength to mitigate market volatility risks[131]. Corporate Governance - All board members attended the board meeting, ensuring collective responsibility for the report[4]. - The company has established a three-year shareholder return plan, which includes cash and stock dividends, approved by the board and shareholders[134]. - The actual controller has guaranteed that the audited net profits for 2020, 2021, and 2022 will not be less than RMB 320 million, RMB 350 million, and RMB 380 million respectively, with corresponding earnings per share of RMB 0.55, RMB 0.60, and RMB 0.66[140]. - The company has committed to maintaining its independence and ensuring business continuity, with a promise not to change its main business for five accounting years post-transfer[140]. Social Responsibility - The company donated over 10 million yuan in medical supplies to support pandemic efforts[75]. - The company emphasizes social responsibility by engaging in various public welfare activities, including supporting impoverished families and students[170]. Financial Position - The company reported a total asset of ¥10,176,547,262.92 and total liabilities of ¥6,096,311,368.55, resulting in a debt-to-asset ratio of 59.91%[180]. - The company's cash and cash equivalents increased by approximately ¥115.18 million, although this was a 49% decrease compared to the previous year[107]. - The company's inventory decreased by 2.00% to approximately 1.15 billion yuan, accounting for 11.34% of total assets[110]. - The company's contract liabilities increased significantly by 222.8%, indicating a rise in customer prepayments[112].

Financial Performance - Net profit attributable to shareholders was ¥91,830,107.31, representing a significant increase of 189.78% year-on-year[13]. - Operating revenue for the period was ¥2,063,978,662.09, up 58.88% from the same period last year[13]. - Basic earnings per share rose to ¥0.16, a 220.00% increase from ¥0.05 in the previous year[13]. - The company reported a net profit increase, with retained earnings growing by 31.80% to 1,567,573,513.82 compared to 1,189,335,164.13 last year[23]. - Net profit for Q1 2021 reached ¥150,312,415.76, compared to ¥51,360,819.10 in Q1 2020, representing a 192.5% increase[36]. - The company reported a comprehensive income total of ¥149,762,975.84 for Q1 2021, significantly higher than ¥52,542,532.58 in Q1 2020[36]. Revenue and Costs - The industrial segment achieved revenue of ¥110,887,894.76, reflecting a growth of 70.70% year-on-year[15]. - The commercial segment generated revenue of ¥1,951,314,922.21, an increase of 58.34% compared to the same period last year[15]. - Operating costs increased by 51.96% to 1,527,402,637.83 from 1,005,115,319.78 in the same period last year[23]. - Total operating costs for Q1 2021 were ¥1,892,868,741.50, up from ¥1,232,353,334.17 in Q1 2020, reflecting a 53.6% increase[35]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥10,993,793,994.54, an increase of 8.03% compared to the end of the previous year[13]. - The company’s total current assets amounted to 6,577,041,939.15, up from 6,227,321,642.97 at the end of 2020[28]. - The company’s total liabilities decreased by 38.04% year-on-year to approximately 333.37 million RMB, primarily due to the repayment of bonds[21]. - The total liabilities reached CNY 6,758,250,471.72, compared to CNY 6,096,311,368.55, indicating an increase of about 10.83%[30]. - The total liabilities as of Q1 2021 amounted to ¥4,625,922,844.72, compared to ¥4,560,899,599.22 in the previous year, showing a slight increase[35]. Cash Flow - The cash flow from operating activities showed a net inflow of -¥202,666,436.57, improving by 26.80% compared to the previous year[13]. - The company’s cash flow from operating activities in Q1 2021 was CNY -202,666,436.57, an improvement from CNY -276,860,521.02 in Q1 2020[41]. - The cash inflow from investment activities in Q1 2021 was CNY 322,419,126.99, down from CNY 508,467,792.64 in Q1 2020[41]. - Cash outflows from operating activities totaled 815,666,555.11 RMB in Q1 2021, down from 1,036,760,499.62 RMB in Q1 2020, showing a reduction of about 21.3%[42]. Strategic Focus - The company plans to continue expanding its market presence and product offerings in the upcoming quarters[18]. - The company is focusing on enhancing its financial structure and operational efficiency through strategic adjustments[19]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[36]. Investments and Equity - Long-term equity investments rose by 61.23% year-on-year to approximately 869.27 million RMB, attributed to acquisitions of new equity stakes[21]. - The equity attributable to shareholders increased to CNY 3,295,019,294.39 from CNY 3,203,387,812.40, a growth of approximately 2.86%[30]. - The company reported a long-term equity investment of CNY 3,868,342,488.99, reflecting its investment strategy[48]. Other Financial Metrics - The weighted average return on equity increased by 1.69 percentage points to 2.83%[13]. - The company reported government subsidies recognized in the current period amounting to ¥4,429,022.61, closely related to normal business operations[16]. - The company reported a significant increase in investment income, reaching CNY 147,979,884.16 in Q1 2021, compared to CNY 59,903,276.03 in Q1 2020[38].

| --- | --- | |-------------------|-----------------------| | | 2020 年第三季度报告 | | 公司代码： 603108 | 公司简称：润达医疗 | | 转债代码： 113588 | 转债简称：润达转债 | 上海润达医疗科技股份有限公司 2020 年第三季度报告 1 / 30 i i Í 三、 四、 Runda 2020 年第三季度报告 目录 | --- | --- | |---------------|-------| | | | | 重要提示 | | | 公司基本情况. | | | 重要事项 | | | | | 附录 2 / 30 2020 年第三季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人赵伟东、主管会计工作负责人廖上林及会计机构负责人（会计主管人员）李娜保 证季度报告中财务报表的真实、准确、完整。 1.4 本公 ...

2020 年半年度报告 公司代码：603108 公司简称：润达医疗 转债代码：113588 转债简称：润达转债 上海润达医疗科技股份有限公司 2020 年半年度报告 1 / 210 2020 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人赵伟东、主管会计工作负责人廖上林及会计机构负责人（会计主管人员）李娜声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，请投 资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司已在本报告第四节 经营情况的讨论 ...

2019 年年度报告 公司代码：603108 公司简称：润达医疗 上海润达医疗科技股份有限公司 2019 年年度报告 1 / 268 2019 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人赵伟东、主管会计工作负责人吴晓强及会计机构负责人（会计主管人员）李娜声 明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 2020年4月28日，公司召开第四届董事会第四次会议，审议通过了《2019年度拟不进行利润 分配的议案》。公司2019年度拟不派发现金红利，不送红股，不以公积金转增股本。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，请投 资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是 ...

2020 年第一季度报告 公司代码：603108 公司简称：润达医疗 上海润达医疗科技股份有限公司 2020 年第一季度报告 1 / 25 Runda 目录 一、 二、 IIÍ 四、 2020 年第一季度报告 | --- | |--------------| | | | 重要提示 | | 公司基本情况 | | 重要事项 | | 附录 | 2 / 25 2020 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人赵伟东、主管会计工作负责人吴晓强及会计机构负责人（会计主管人员）李娜保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-------------------------------------------------|---------------- ...